[iHuman Seminar] Alzheimer’s Disease: Translating Mechanism of Pathogenesis to Precision Medicine

ON2024-04-09TAG: ShanghaiTech UniversityCATEGORY: Lecture

Topic: Alzheimer’s Disease: Translating Mechanism of Pathogenesis to Precision Medicine

Speaker: Professor Chen Xian, School of Medicine, University of North Carolina-Chapel Hill (UNC)

Date and time: April 11, 10:00–11:00

Venue: Auditorium, Y Building

Host: Shui Wenqing


Abstract:

By  combining approaches including AD pathology-correlated chemoproteomics  and proteomics, we discovered G9a-mediated translation regulatory  mechanism of AD pathogenesis that defines the pathologies of AD.  Accordingly, we developed a novel brain-penetrant inhibitor of G9a,  MS1262, to block this G9a-regulated translation mechanism. Intermittent  MS1262 treatment of multiple AD mouse models consistently restored both  cognitive and noncognitive functions to healthy levels. Comparison of  proteomic data of MS1262-treated AD mice with human AD patient data  revealed that G9a regulates multiple pathological brain pathways that  elaborate Aß plaque and neurofibrillary tangles, the hallmarks of AD  progression. From these pathways, we identified MS1262-affected  biomarkers of early-stage AD. This mouse-to-human conservation of  G9a-regulated translation of AD suggests that the global, multifaceted  restoration effects of MS1262 in mice could extend to relieve major  symptoms of AD patients.


Biography:

Dr.  Chen Xian is the Professor and Director of Technology Development at  UNC Proteomic Center, and he is also the Founder of TransChromix  Therapeutics. He has a long-standing interest in understanding the  molecular pathways and mechanisms underlying autoinflammation-associated  diseases such as cancer, sepsis, Alzheimer’s disease, and diabetes  using his multi-disciplinary expertise. He has authored and co-authored  more than 160 papers including some in Nature, Science, Cell, Nature Immunology, Cell Stem Cell, Molecular Cell, Immunity, Cancer DiscoveryNature Cancer, Science Advances, Nature Communications,  etc. He also holds five patents and two US provisional patent  applications for New Therapeutics for Alzheimer’s disease and COVID-19.  His H-index is at 67 with 38613 citations.